Disputing earlier studies it now seems that facial transplantation is a safer option. Rita Alloway, PharmD, and Steve Woodle, MD, of the University of Cincinnati (UC), and a University of Louisville team led by John Barker, MD, PhD. Believe that the immunosuppressive risks is much lesser than previously thought. This has far reaching implications as it would now be a safer option for people who have suffered severe facial injuries. They also suggest that the previous data on the risks involved were quite misleading. The report is published in the September edition of the journal Plastic and Reconstructive Surgery.
The first recorded facial transplant was performed in France in 2005 on a 38-year-old woman whose nose, lips and chin had been bitten off by a dog. Tissues, muscles, arteries and veins were taken from a brain-dead donor and successfully transplanted to the patient's lower face.
There have been only two similar attempts since.
According to Woodle, however, the report did not provide the best risk assessment.
"In estimating the risks of immunosuppression for face transplant recipients, the biggest problem is comparing apples to oranges," Woodle says. "What we have tried to do is to address the apples and oranges problem by a comprehensive and up-to-date consideration of the issue."
Both the health status of solid organ transplant recipients and the tissue composition of the solid organs reported in the earlier studies are very different from that of face transplant recipients and their facial tissues, he says.
In the current study, the Cincinnati and Louisville researchers compared the 2004 data with that taken from clinical studies describing kidney and hand transplants using the latest immunosuppression techniques.
They found the outcomes to be very different from those in the 2004 study.
Based on kidney and hand transplantation cases, in which the same drug regimen was used, researchers found that acute, or immediate, rejection may occur in 10 to 70 percent of patients. In of all these cases, however, rejection was reversible by adjusting the immunosuppression medications.
They also found that fewer than 10 percent of patients would experience chronic rejection over five years.
"In considering the most recent and relevant data, we came to the conclusion that the expectations for face transplant recipients should be significantly better than those previously published," Woodle says.
Coauthor Barker says that the lack of comparable "apples-to-apples" risk data in the field has led to debate over the ethics of face transplantation, which was the inspiration for Cincinnati-Louisville study.
"This risk-benefit equation is at the center of controversy over facial transplantation," he says. "Physicians and scientists question whether the risks of life-long immunosuppression for patients justify the benefits of this new treatment."
Cincinnati coauthor Alloway says that physicians often don't realize how much patients will endure to gain relief.
"Surveys from transplant professionals have shown that doctors underestimate what people will do for a cure," Alloway says. "Often, living disfigured is worse than risk associated with this sort of operation and the immunosuppressive risks that accompany it."
Researchers hope this study will provide a solid foundation for future work with facial transplantation.
"We're trying to meld the fields of transplantation and immunosuppression to produce maximum expertise on the subject," Alloway continued. "We're hoping to decrease toxicity and create a more manageable risk spectrum for surgeons and patients."
Other coauthors on the study were Allen Furr, PhD, Joseph Banis, Jr., MD, Rachael Ashcroft, and Dalidor Vasilic, MD, from the University of Louisville as well as and Moshe Kon, MD, PhD, from the University of Utrecht, Netherlands.